Product/Composition:- | Lapatinib |
---|---|
Strength:- | 250 mg, 500 mg |
Form:- | Tablet |
Reference Brands:- | Tykerb® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Lapatinib is a targeted therapy for HER2-positive breast cancer, available in 250 mg and 500 mg oral tablets. Marketed as Tykerb® by GlaxoSmithKline, it inhibits the HER2 receptor to prevent cancer cell growth. Available in the US and EU, Lapatinib is sourced by B2B pharmaceutical wholesalers, ensuring reliable supply and GMP-compliant distribution for oncology clinics at competitive prices.
Lapatinib is a targeted cancer therapy used in the treatment of HER2-positive breast cancer. As a tyrosine kinase inhibitor (TKI), it inhibits the HER2 receptor, a key driver of cancer cell growth. Available in 250 mg and 500 mg oral tablets, Lapatinib is marketed under the brand name Tykerb® by GlaxoSmithKline and is also available in generic forms. Widely sourced by B2B pharmaceutical wholesalers in the US and EU, Lapatinib ensures reliable supply for oncology clinics and cancer centers. Its GMP-compliant distribution offers competitive pricing, making it a key player in breast cancer treatment.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications